Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Key Studies Influencing My Practice Following IAS 2021—Audio Recap

July 18-21, 2021; Virtual
Listen to expert insights from Babafemi Taiwo, MBBS, on updates from IAS 2021, including new data on COVID-19 and HIV, 2-drug ART, long-acting injectable ART, investigational agents, and new therapies for multidrug-resistant tuberculosis.
Babafemi Taiwo, MBBS
Released: August 19, 2021

In this episode, Babafemi Taiwo, MBBS, discusses new HIV data from IAS 2021, including:

  • WHO Global Clinical Platform: COVID-19 outcomes in PWH
  • 2-drug regimen of DTG/3TC: efficacy, metabolic outcomes (TANGO)
  • Investigational antiretroviral use
    • CAB LA + RPV LA in treatment-naive PWH (FLAIR)
  • Investigational antiretroviral agents
    • LEN (CAPELLA, CALIBRATE)
    • ISL (P011, P016)
  • Alternative BPaL dosing in treatment of drug-resistant TB (ZeNix)

Follow along with an expanded slideset at: https://bit.ly/3syWD5T

Information on this Educational Activity

Faculty

Babafemi Taiwo, MBBS

Gene Stollerman Professor of Medicine
Chief,
Division of Infectious Diseases
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Babafemi Taiwo, MBBS, has disclosed that he has received consulting fees from Gilead Sciences, Merck, and ViiV Healthcare and funds for research support from Janssen.

Program Medium

This program has been made available online.

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
Supported by educational grants from
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
Merck Sharp & Dohme Corp.
ViiV Healthcare

Related Content

Dr Neha Pandit discusses barriers and solutions to PrEP uptake in key patient populations in this commentary from Clinical Care Options (CCO)

person default Neha Pandit, PharmD, AAHIVP, BCPS Released: December 2, 2022

Dr Monica Gandhi discusses key advances in HIV treatment over the past year, from Clinical Care Options (CCO)

Monica Gandhi, MD, MPH Released: December 2, 2022

A patient advocate discusses the importance of community-led HIV treatment and prevention, from Clinical Care Options (CCO)

person default Rena Janamnuaysook, MBA Released: December 2, 2022

Clinical Care Options (CCO) expert analysis of new data from IDWeek and HIV Glasgow 2022, provided by expert HIV faculty

Joseph J. Eron, Jr., MD Karine Lacombe, MD, PhD Released: November 30, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings